Spontaneously-reported adverse events are collected to monitor the safety of drugs once they reach the market. Analyzing these data require techniques that are distinct from those used in the analysis of adverse events from clinical trials. Richard Zink discusses these differences, describes common methods to measure disproportionality and illustrates these techniques using JMP Clinical.

Register now for this free Webinar.

*
*
*
*
*
  Please subscribe me to JMP Newswire, the monthly newsletter for JMP users.
  Yes, you may send me emails occasionally about JMP products and services. I understand that I can withdraw my consent at any time by clicking the opt-out link in the emails.

JMP is a division of SAS Institute Inc. and your information will be handled in accordance with the SAS Privacy Statement.

 
 

Back to Top